Klin Farmakol Farm. 2018;32(4):10-14 | DOI: 10.36290/far.2018.032

Current pharmacotherapy of tuberculosis

Jiří Wallenfels1, Martina Vašáková2, Ivan Solovič3
1 Národní jednotka dohledu nad tuberkulózou, Nemocnice Na Bulovce, Praha
2 Pneumologická klinika 1. LF UK a TN Praha
3 NUTPCHaHCH Vyšné Hágy, Katolícka univerzita Ružomberok

Tuberculosis still represents global threat, with respect both to the number of infected, ill and dead individuals. Increasing incidenceof resistant forms of tuberculosis with significantly worse treatment outcomes compared with sensitive tuberculosisposes a concern. New antituberculotics and antibiotics prescribed until now mainly for other infections are starting to be usedfor treatment of resistant tuberculosis. New, more effective, shorter and better tolerated treatment coarses are investigated. Thecurrent epidemiologic situation in the Czech Republic is relatively favourable, it is appropriate to discuss about the obligation tohospitalize all patients with tuberculosis.

Keywords: tuberculosis, epidemiology, treatment, antituberculotics, latent infection

Received: July 12, 2019; Accepted: July 25, 2019; Prepublished online: August 16, 2019; Published: January 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Wallenfels J, Vašáková M, Solovič I. Current pharmacotherapy of tuberculosis. Klin Farmakol Farm. 2018;32(4):10-14. doi: 10.36290/far.2018.032.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Houben RMGJ, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med 2016; 13(10): e1002152. Go to original source... Go to PubMed...
    2. Global tuberculosis report. Geneva: World Health Organization; 2018. Go to PubMed...
    3. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2018-2016 data.
    4. Stockholm: European Centre for Disease Prevention and Control, 2018.
    5. ÚZIS ČR. Základní přehled epidemiologické situace ve výskytu tuberkulózy v České republice v roce 2017. [online]. [cit. 2018-10-21]. Dostupné z: http://www.uzis.cz/katalog/zdravotnicka-statistika/tuberkuloza-respiracni-nemoci
    6. Zatloukal P, Kos S, Vašáková M. Tuberkulóza dospělých, Standard léčebného plánu, aktualizace 2016. [online]. [cit. 2018-10-21]. Dostupné z: http://www.pneumologie.cz/guidelines/.
    7. Vašáková M, Hricíková I, Kopecká E. Současný přístup k diagnostice a léčbě tuberkulózy. Remedia 2016; 26: 236-241.
    8. Hricíková I, Žáčková P, Vašáková M. Tuberkulóza. In Vašákov, M.A. kol. Moderní farmakoterapie v pneumologii. Praha: Maxdorf, 1. vyd., 2013: 197-209.
    9. Kingston W. Streptomycin, Schatz v. Waksman, and the balance of credit for discovery. J Hist Med Allied Sci. 2004; 59(3): 441-462. Go to original source... Go to PubMed...
    10. ČPFS. Lidí s tuberkulózou mírně ubylo. Tisková zpráva. Praha 2018. [online]. [cit. 2018-10-21]. Dostupné z: http://www.pneumologie.cz/stranka/1028/tiskove-zpravy/
    11. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World Health Organization; 2017. Go to PubMed...
    12. WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. Geneva: World Health Organization; 2018. Go to PubMed...
    13. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB).
    14. Stop TB Partnership. WHO's Rapid Communication on Treatment of Multidrug- and Rifampicin-Resistant Tuberculosis. Stop TB Partnership's Statement On Implications for TB Programmes. [online]. [cit. 2018-10-21]. Dostupné z: http://www.stoptb.org/news/stories/2018/ns18_061.asp.
    15. Homolka J. Doporučení pro biologickou léčbu preparáty blokujícími účinek TNF alfa, aktualizace 2016. [online]. [cit. 2018-10-21]. Dostupné z: http://www.pneumologie.cz/guidelines/.
    16. Polcová V, Vašáková M, Valentová-Bartáková L. Tuberkulóza a LTBI u pacientů před a po transplantaci solidních orgánů či hematopoetických kmenových buněk. (Doporučený postup diagnostiky a léčby). [online]. [cit. 2018-10-21]. Dostupné z: http://www.pneumologie.cz/guidelines/.
    17. Homolka J a členové Sekce pro TB při ČPFS. Doporučení Sekce pro tuberkulózu při ČPFS pro diagnostiku a léčbu latentní TB infekce u nemocných v chronickém dialyzačním léčení. Stud. Pneumol. Phthiseol. 2018; 78(1): 10-11.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.